Hims & Hers Health (NYSE:HIMS) Rating Increased to Hold at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a sell rating to a hold rating in a report issued on Saturday morning.

A number of other research firms also recently commented on HIMS. UBS Group set a $23.00 price target on shares of Hims & Hers Health in a research report on Friday, May 22nd. TD Cowen increased their price objective on shares of Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday. Morgan Stanley raised their price objective on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Tuesday. JPMorgan Chase & Co. dropped their target price on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of “Hold” and a consensus price target of $32.43.

Check Out Our Latest Analysis on HIMS

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $28.15 on Friday. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $65.30. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 1.56. The firm has a market capitalization of $6.57 billion, a price-to-earnings ratio of -44.68 and a beta of 2.40. The business has a 50 day simple moving average of $32.11 and a 200 day simple moving average of $26.09.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. Hims & Hers Health’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same period last year, the business posted $0.17 earnings per share. On average, equities research analysts anticipate that Hims & Hers Health will post -0.05 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 7,163 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $36.49, for a total transaction of $261,377.87. Following the completion of the sale, the chief financial officer directly owned 284,321 shares in the company, valued at approximately $10,374,873.29. This trade represents a 2.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David B. Wells purchased 48,400 shares of the firm’s stock in a transaction on Tuesday, May 26th. The stock was acquired at an average price of $24.23 per share, for a total transaction of $1,172,732.00. Following the transaction, the director owned 224,417 shares of the company’s stock, valued at $5,437,623.91. The trade was a 27.50% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders sold 83,126 shares of company stock valued at $2,711,339. Corporate insiders own 11.76% of the company’s stock.

Institutional Investors Weigh In On Hims & Hers Health

Several hedge funds have recently modified their holdings of HIMS. Versant Capital Management Inc raised its holdings in Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after buying an additional 665 shares during the period. MassMutual Private Wealth & Trust FSB lifted its stake in Hims & Hers Health by 70.0% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after buying an additional 319 shares in the last quarter. Binnacle Investments Inc acquired a new position in shares of Hims & Hers Health in the third quarter worth about $28,000. Bogart Wealth LLC increased its position in shares of Hims & Hers Health by 235.8% in the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after acquiring an additional 632 shares in the last quarter. Finally, Geneos Wealth Management Inc. purchased a new position in shares of Hims & Hers Health in the first quarter worth approximately $30,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

  • Positive Sentiment: Management raised its full-year revenue outlook to approximately $3.1 billion–$3.3 billion, while second-quarter revenue increased 38% year over year to $753.2 million. The guidance suggests continued demand for Hims & Hers’ telehealth and weight-management offerings. Hims & Hers Raised Guidance
  • Positive Sentiment: Bank of America and Needham analysts reportedly maintained constructive views on HIMS, supporting the bullish case that subscriber growth, expanding services, and the company’s longer-term healthcare platform can outweigh near-term volatility. Bank of America Analyst Forecast Needham Analyst Forecast
  • Neutral Sentiment: Analyst opinion is divided: Citigroup issued a more pessimistic forecast, highlighting valuation and execution risks as Hims & Hers transitions its weight-loss business. Citigroup Forecast
  • Negative Sentiment: The company’s gross margin fell six percentage points sequentially to 64% as branded GLP-1 drugs increased revenue but produced less favorable economics. The earnings report also included an adjusted loss of $0.37 per share, substantially below the $0.05 loss analysts expected, increasing concerns that growth is coming at the expense of profitability. Hims & Hers Margin Analysis
  • Negative Sentiment: Several law firms, including Kaplan Fox, Kessler Topaz, Glancy Prongay Wolke, and Howard G. Smith, announced investigations into potential securities-law violations. These announcements are investor-solicitation notices rather than findings of wrongdoing, but they add headline, litigation, and reputational risk following the Federal Trade Commission’s lawsuit against the company. Kaplan Fox Investigation Kessler Topaz Investigation

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

See Also